Recursion Pharmaceuticals price to sales ratio RXRX

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: 36.1×
5-year median: 39.1×
Against its 5-year history: 39th; percentile: 0 is its lowest day, 100 its highest
5-year range: 20.8× to 132×
Peer median: 6.8×

Recursion Pharmaceuticals' price to sales ratio is 36.1× as of Oct 23, 2026.

That is below its 5-year median of 39.1×, close to the middle of its last 5 years.

Over that time it ranged from 20.8× in Mar 2026 to 132× in Aug 2022.

The median for 10 biotech stocks of a similar size is 6.8×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	36.1×	20.8×	56.4×
2025	50.6×	27.7×	56.1×
2024	32.5×	25.1×	67.4×
2023	45.1×	21.8×	63.8×
2022	50.9×	49.6×	132×

Against its peers

Companies in Biotechnology nearest Recursion Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
RXRXRecursion Pharmaceuticals	36.1×
VCELVericel	7.1×
ADMAAdma Biologics	4.7×
MGTXMeiraGTx	2.2×
KRYSKrystal Biotech	20.9×
RGENRepligen	12.7×
TECHBIO-TECHNE	9.4×
HALOHalozyme Therapeutics	8.6×
NBIXNeurocrine Biosciences	4.3×
EXELExelixis	6.6×
PLXProtalix BioTherapeutics	2.5×
Peer median	6.8×

Where Recursion Pharmaceuticals ranks

#58of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Recursion Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.